You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide with rituximab for previously treated follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA627
  • Published:  07 April 2020
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 142 KB)

    Published:
    07 April 2020

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 271 KB)

    Published:
    27 February 2020
  • Committee papers (PDF 10.6 MB)

    Published:
    27 February 2020
  • Public committee slides (PDF 1.24 MB)

    Published:
    27 February 2020

Invitation to participate

  • Final scope (PDF 181 KB)

    Published:
    17 May 2019
  • Final stakeholder list (PDF 215 KB)

    Published:
    17 May 2019
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 180 KB)

    Published:
    17 May 2019
  • Equality impact assessment (Scoping) (PDF 123 KB)

    Published:
    17 May 2019
Back to top